Low serum A-SYNUCLEIN and oligomer A-SYNUCLEIN levels in multiple sclerosis patients

Creative Commons License

Bilge N., Simsek F., Yevgi R., Ceylan M., Askın S.

JOURNAL OF NEUROIMMUNOLOGY, cilt.350, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 350
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.jneuroim.2020.577432
  • Dergi Adı: JOURNAL OF NEUROIMMUNOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Psycinfo, Veterinary Science Database
  • Atatürk Üniversitesi Adresli: Evet

Özet

Introduction: Multiple sclerosis (MS) is an autoimmune, inflammatory, demyelinating neurodegenerative disease progressing with attacks. Alpha-synuclein (alpha-Syn), a neuronal protein, has been previously associated with the inflammation and development of neurodegenerative diseases. Although the cause of neurodegeneration in multiple sclerosis is mainly associated with inflammation, alpha-Syn may play a role in the pathogenesis of MS, as in other classical neurodegenerative diseases such as synucleinopathies. In multiple sclerosis, alpha-Syn has been directly studied in central nervous system lesions and cerebrospinal fluid (CSF). However, there are few studies approaching variations in peripheral alpha-Syn in MS. The aim of our study was to investigate the correlation between disease progression and other clinical parameters by measuring serum alpha-Syn and oligomer alpha-Syn levels in MS patients.